Commercialization and regulation of regenerative medicine products : Promises, advances and challenges
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
The ultimate goal of regenerative medicine is to repair, regenerate, or reconstruct functional loss in failed tissues and/or organs. Although regenerative medicine is a relatively new field, multiple diverse research groups are helping regenerative medicine reach its objectives. All endeavors in this field go through in silico, in vitro, in vivo, and clinical trials which are prerequisites to translating such approaches from the bench to the bedside. However, despite such promise, there are only a few regenerative medicine approaches that have actually entered commercialization due to extensive demands for the inclusion of multiple rules, principles, and finances, to reach the market. This review covers the commercialization of regenerative medicine, including its progress (or lack thereof), processes, regulatory concerns, and immunological considerations to name just a few key areas. Also, commercially available engineered tissues, including allografts, synthetic substitutes, and 3D bioprinting inks, along with commercially available cell and gene therapeutic products, are reviewed. Clinical applications and future perspectives are stated with a clear road map for improving the regenerative medicine field.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:153 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 153(2022) vom: 08. Sept., Seite 113431 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beheshtizadeh, Nima [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Commercialization |
|---|
| Anmerkungen: |
Date Completed 12.09.2022 Date Revised 12.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2022.113431 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345936272 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345936272 | ||
| 003 | DE-627 | ||
| 005 | 20231226030235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2022.113431 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1153.xml |
| 035 | |a (DE-627)NLM345936272 | ||
| 035 | |a (NLM)36076549 | ||
| 035 | |a (PII)S0753-3322(22)00820-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beheshtizadeh, Nima |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Commercialization and regulation of regenerative medicine products |b Promises, advances and challenges |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.09.2022 | ||
| 500 | |a Date Revised 12.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a The ultimate goal of regenerative medicine is to repair, regenerate, or reconstruct functional loss in failed tissues and/or organs. Although regenerative medicine is a relatively new field, multiple diverse research groups are helping regenerative medicine reach its objectives. All endeavors in this field go through in silico, in vitro, in vivo, and clinical trials which are prerequisites to translating such approaches from the bench to the bedside. However, despite such promise, there are only a few regenerative medicine approaches that have actually entered commercialization due to extensive demands for the inclusion of multiple rules, principles, and finances, to reach the market. This review covers the commercialization of regenerative medicine, including its progress (or lack thereof), processes, regulatory concerns, and immunological considerations to name just a few key areas. Also, commercially available engineered tissues, including allografts, synthetic substitutes, and 3D bioprinting inks, along with commercially available cell and gene therapeutic products, are reviewed. Clinical applications and future perspectives are stated with a clear road map for improving the regenerative medicine field | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Commercialization | |
| 650 | 4 | |a Immunological considerations | |
| 650 | 4 | |a Regenerative medicine | |
| 650 | 4 | |a Regulatory concerns | |
| 650 | 4 | |a Tissue engineering | |
| 700 | 1 | |a Gharibshahian, Maliheh |e verfasserin |4 aut | |
| 700 | 1 | |a Pazhouhnia, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Rostami, Mohammadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Zangi, Ali Rajabi |e verfasserin |4 aut | |
| 700 | 1 | |a Maleki, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Azar, Hanieh Kolahi |e verfasserin |4 aut | |
| 700 | 1 | |a Zalouli, Vahideh |e verfasserin |4 aut | |
| 700 | 1 | |a Rajavand, Hosnieh |e verfasserin |4 aut | |
| 700 | 1 | |a Farzin, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Lotfibakhshaiesh, Nasrin |e verfasserin |4 aut | |
| 700 | 1 | |a Sefat, Farshid |e verfasserin |4 aut | |
| 700 | 1 | |a Azami, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Webster, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Nima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 153(2022) vom: 08. Sept., Seite 113431 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:153 |g year:2022 |g day:08 |g month:09 |g pages:113431 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2022.113431 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 153 |j 2022 |b 08 |c 09 |h 113431 | ||